ADIAL PHARMACEUTICALS, INC.(ADIL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ADIL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ADIAL PHARMACEUTICALS, INC. (ADIL), a Healthcare sector company. ADIL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), ADIAL PHARMACEUTICALS, INC. reports net income of $-2.0M, free cash flow of $-1.6M. Top institutional holders of ADIL by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, Manchester Capital Management, based on the most recent SEC filings. ADIL trades on the Nasdaq exchange and files with the SEC under CIK 1513525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADIAL PHARMACEUTICALS, INC. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.0M
Free Cash Flow
Q1 2026
$-1.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+39.6% YoYOperating Income
+5.9% YoYEPS (Diluted)
+82.5% YoYTotal Assets
+32.3% YoYOp. Cash Flow
+6.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-8.0M +39.6% | $-13.2M -157.6% | $-5.1M +73.6% | $-19.4M -78.3% | $-10.9M -26.8% | $-8.6M |
| Operating Income | $-7.8M +5.9% | $-8.3M -20.3% | $-6.9M +64.3% | $-19.3M -76.5% | $-10.9M -32.5% | $-8.2M |
| EPS (Diluted) | $-11.93 +82.5% | $-68.01 -1789.2% | $-3.60 -246.2% | $-1.04 | — | — |
| Total Assets | $6.7M +32.3% | $5.0M +6.5% | $4.7M -36.6% | $7.5M +36.1% | $5.5M -28.5% | $7.7M |
| Operating Cash Flow | $-6.5M +6.2% | $-6.9M -1.7% | $-6.8M +43.0% | $-11.9M -56.5% | $-7.6M -20.4% | $-6.3M |
Get alerted when ADIL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ADIAL PHARMACEUTICALS, INC. including:
Top Institutional Holders of ADIL
GEODE CAPITAL MANAGEMENT, LLC
$43.4K24,249 shVANGUARD FIDUCIARY TRUST CO
$10.5K5,879 shManchester Capital Management LLC
$3.4K1,923 shTower Research Capital LLC (TRC)
$2.4K1,356 shBlackRock, Inc.
$2.0K1,110 shUBS Group AG
$970.00542 shVANGUARD CAPITAL MANAGEMENT LLC
$646.00361 shMORGAN STANLEY
$90.0050 shSBI Securities Co., Ltd.
$84.0047 shCaitong International Asset Management Co., Ltd
$27.0015 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $43.4K | 24,249 |
| VANGUARD FIDUCIARY TRUST CO | $10.5K | 5,879 |
| Manchester Capital Management LLC | $3.4K | 1,923 |
| Tower Research Capital LLC (TRC) | $2.4K | 1,356 |
| BlackRock, Inc. | $2.0K | 1,110 |
| UBS Group AG | $970.00 | 542 |
| VANGUARD CAPITAL MANAGEMENT LLC | $646.00 | 361 |
| MORGAN STANLEY | $90.00 | 50 |
| SBI Securities Co., Ltd. | $84.00 | 47 |
| Caitong International Asset Management Co., Ltd | $27.00 | 15 |
More Healthcare Companies
View all Healthcare →Put ADIL on your watchlist
Track score changes the day ADIAL PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ADIL a good stock to buy?
13F Pro's AI-powered analysis of ADIAL PHARMACEUTICALS, INC. (ADIL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADIL are available on the ADIL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ADIL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADIL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ADIAL PHARMACEUTICALS, INC.'s investment landscape.